Alector (ALEC) Stock Price, News & Analysis

Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.66 to $1.72
• 50-Day Range: $1.64 to $5.55
• 52-Week Range: $1.60 to $7.58
• Volume: 529,390 shs
• Average Volume: 1.23 million shs
• Market Capitalization: $167.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.75
• Consensus Rating: Hold

Alector Stock Analysis - MarketRank™

Alector scored higher than 90% of companies evaluated by MarketBeat, and ranked 107th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Alector has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 2 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Alector has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alector are expected to decrease in the coming year, from ($1.88) to ($1.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alector is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alector is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alector has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.84% of the float of Alector has been sold short.

Short Interest Ratio / Days to Cover

Alector has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Alector has recently decreased by 8.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alector does not currently pay a dividend.

Dividend Growth

Alector does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.92

Percentage of Shares Shorted

6.84% of the float of Alector has been sold short.

Short Interest Ratio / Days to Cover

Alector has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Alector has recently decreased by 8.50%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.58

News Sentiment

Alector has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Alector this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for ALEC on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alector to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $239,806.00 in company stock.

Percentage Held by Insiders

Only 9.10% of the stock of Alector is held by insiders.

Percentage Held by Institutions

85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALEC Stock Analysis - Frequently Asked Questions

How have ALEC shares performed this year?

Alector's stock was trading at $1.89 at the beginning of the year. Since then, ALEC stock has decreased by 9.5% and is now trading at $1.71.
View the best growth stocks for 2025 here.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.10. The firm earned $15.34 million during the quarter, compared to analyst estimates of $16.33 million. Alector had a negative net margin of 257.54% and a negative trailing twelve-month return on equity of 108.77%.

Does Alector have any subsidiaries?

Alector subsidiaries include these companies: Alector LLC.

When did Alector IPO?

Alector (ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Who are Alector's major shareholders?

Alector's top institutional investors include Nordea Investment Management AB (0.17%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Polaris Venture Management Co, Arnon Rosenthal, Sara Kenkare-Mitra, Robert King, Marc Grasso, Gary Romano and Paula Hammond.
View institutional ownership trends.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 2/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALEC
• CUSIP: N/A
• CIK: 1653087
• Web: www.alector.com
• Phone: (415) 231-5660
• Fax: N/A
• Employees: 270
• Year Founded: 2013

Price Target and Rating

• Average Stock Price Target: $3.75
• High Stock Price Target: $7.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +119.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-130,390,000.00
• Net Margins: -257.54%
• Pretax Margin: -254.70%
• Return on Equity: -108.77%
• Return on Assets: -27.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.29
• Quick Ratio: 3.29

Sales & Book Value

• Annual Sales: $97.06 million
• Price / Sales: 1.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 1.21

Miscellaneous

• Outstanding Shares: 97,930,000
• Free Float: 89,021,000
• Market Cap: $167.46 million
• Optionable: Optionable
• Beta: 0.57